Hospital ward surveillance technologies still lack a clear effectiveness ranking in this Bayesian network meta-analysis. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-clinical-surveillance-technologies-non-icu-bayesian-network-meta-analysis-2026-09-24

Value-based price shifts with population eligibility: GBP 4,410 at list price, GBP 612 for the top tenth. https://www.mattheneus.com/editorial/cost-effectiveness-demand-curve-value-based-price-population-eligibility-2026-09-25 #HTA #HealthEconomics

A costed menu for global evidence synthesis infrastructure puts 40 solutions at US$278.3 million. https://www.mattheneus.com/editorial/evidence-synthesis-infrastructure-costed-menu-data-duplication-investment-2026-09-21 #HTA #EvidenceSynthesis #HealthEconomics

Six ways to record ethnicity, 21 ways to group it: subgroup comparisons stop meaning the same thing across studies. https://www.mattheneus.com/editorial/race-ethnicity-ascertainment-categorisation-clinical-research-subgroup-comparability-2026-09-21 #HTA #EvidenceSynthesis

G-BA resumes three stem cell transplantation assessments in multiple myeloma. https://www.mattheneus.com/editorial/g-ba-stem-cell-transplantation-multiple-myeloma-assessment-resumption-2026-09-24 #HTA #EvidenceSynthesis #Pharma

MHRA opens a call for evidence on AI for medicines safety, reaching beyond ADMET into validation and governance. https://www.mattheneus.com/editorial/mhra-beyond-admet-ai-medicines-safety-call-for-evidence-2026-09-22 #HTA #RegulatoryAffairs #RWE

Capacity-based exclusions in trial protocols quietly narrow the population HTA bodies must later generalise to. https://www.mattheneus.com/editorial/clinical-trial-protocol-capacity-exclusions-population-relevance-2026-09-25 #HTA #EvidenceSynthesis #RegulatoryAffairs

The European Commission has opened its fourth 2026 request period for joint scientific consultations, with an October deadline. #HTA #RegulatoryAffairs https://www.mattheneus.com/editorial/european-commission-fourth-joint-scientific-consultation-request-period-october-2026-deadline

The MHRA is proposing a faster scientific advice route and fee rebates from April 2027, reshaping early regulatory engagement budgets. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/mhra-statutory-fees-2027-scientific-advice-accelerated-route-rebate-proposals

Most public health randomised trials report benefits and leave the harms column empty, which quietly distorts economic evaluation. #HTA #EvidenceSynthesis https://www.mattheneus.com/editorial/public-health-randomised-trials-harms-reporting-programme-economic-evaluation-2026-09-25

#dostarlimab #jemperli #atezolizumab #tecentriq #patientvoice #HTA #chemotherapy #patientinput #patient #survivor #caregiver #survey #HTAsubmission #colorectalcancer #cancer #colorectal #colon #rectal #treatment #therapy #realworldevidence #patientexperience

Zilucoplan in generalised myasthenia gravis: PubMed indexes MAIC results vs IVIg and two complement inhibitors.

https://www.mattheneus.com/editorial/pubmed-zilucoplan-generalised-myasthenia-gravis-matching-adjusted-indirect-comparison-2026-09-24

#HTA #MAIC #EvidenceSynthesis

Australia opens consumer and clinician seats on its HTA reform reference group. https://www.mattheneus.com/editorial/australia-hta-reform-implementation-reference-group-consumer-clinician-expression-of-interest-2026-09-22 #HTA #RegulatoryAffairs

Indices built to predict death explain little of what patients cost. Cost prediction needs a cost-based comorbidity index. https://www.mattheneus.com/editorial/cost-based-comorbidity-index-rxrisk-charlson-elixhauser-cost-prediction-2026-09-25 #HTA #HealthEconomics #RWE

In under-fives, cost-utility models still lean on utility instruments validated in adults, and most studies never flag the substitution. https://www.mattheneus.com/editorial/paediatric-under-five-cost-utility-adult-utility-instruments-reporting-gap-2026-09-25 #HTA #HealthEconomics #EvidenceSynthesis

Poland backs adjuvant Phesgo only for surgically confirmed node-positive breast cancer. https://www.mattheneus.com/editorial/aotmit-phesgo-pertuzumab-trastuzumab-adjuvant-breast-cancer-node-positive-restriction-2026-09-25 #HTA #Pharma

Germany forms a ustekinumab reference-price group covering prefilled pens and syringes. https://www.mattheneus.com/editorial/g-ba-ustekinumab-reference-price-group-stage-one-parenteral-forms-2026-09-25 #HTA #Pharma #HealthEconomics

Nearly 18 hours of avoided caregiving a year, derived from patient utilities alone. How informal care spillover enters societal value. https://www.mattheneus.com/editorial/informal-care-time-spillover-societal-value-patient-utility-derivation-2026-09-18 #HTA #HealthEconomics

Restrict a rapid review to the usual databases and relative recall quietly decides which trials you never see. Topic-specific sources change the answer. https://www.mattheneus.com/editorial/rapid-review-database-restriction-relative-recall-topic-specific-databases-2026-09-24 #HTA #EvidenceSynthesis

HPPA is proud to attend the annual Hawaiʻi Tourism Authority conference in Waikiki, on Oahu, this week. Tropical Storm Nolo is a concern but not affecting the two day gathering. The conference theme: Ke Kahu o ka Mālamalama, Guardians of the Light.
Day Two is tomorrow!

#HPPA #HTA